Mark Smith (Finch)
Past a turning point, Finch scores $90M to complete the final stretch for oral microbiome therapy
Back in 2017, Finch Therapeutics was born, shrouded in the ashes of an implosion at Seres Therapeutics that clouded the whole microbiome field. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
